Intersect ENT’s Ascend study misses endpoint
Intersect ENTÂ (NSDQ:XENT) shares plunged today after the company said it failed to meet the primary endpoint in a study of its Ascend investigational drug-coated sinus balloon. The 70-person, randomized, double-blind trial was designed to compared treatment with Intersect ENT’s DCB when randomized against an uncoated balloon control. The study missed the primary endpoint, frontal sinus … Continue reading Intersect ENT’s Ascend study misses endpoint
Copy and paste this URL into your WordPress site to embed
Copy and paste this code into your site to embed